Clinical trials
Clinically Significant Prostate Cancer clinical trials
Below are recruiting clinically significant prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 307 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07339943Recruiting
Focal laser ablation for intermediate-risk prostate cancer
This trial tests a new way to treat intermediate-risk prostate cancer using a targeted laser guided by micro-ultrasound and MRI. It aims to see if this less invasive approach is safe and effective for men who have not had prior prostate cancer treatments.
Toronto, OntarioAges 40–85 - NCT02526368RecruitingEarly Phase 1
Scan your prostate with special MRI using pyruvate to find high-grade cancer
This trial tests whether a specialized MRI scan using a pyruvate tracer can better detect high-grade (more aggressive) prostate cancer. It may help doctors find cancer more accurately and guide treatment decisions or targeted follow-up.
San Francisco, CaliforniaAges 18 years+ - NCT06178354Recruiting
Freezing or ultrasound for early prostate cancer
This trial is testing whether freezing (cryotherapy) or using high-frequency ultrasound (HIFU) to destroy only the cancer spots in the prostate is safe and effective for men with early-stage prostate cancer. It's a less invasive option that targets just the tumor, not the whole prostate.
Sacramento, CaliforniaAges 18 years+ - NCT07028853RecruitingPhase 3
New drug combo for advanced prostate cancer
This study tests whether adding the investigational drug mevrometostat to the standard treatment enzalutamide works better than enzalutamide alone for men with prostate cancer that has spread to other parts of the body (metastatic castration-sensitive prostate cancer). You may benefit if you haven't yet received chemotherapy or similar strong treatments for this stage of cancer.
Huntsville, AlabamaAges 18 years+ - NCT07414940RecruitingPhase 1/Phase 2
Actinium-225 PSMA for advanced prostate cancer after Lu-177
This trial tests a new targeted radiation drug called actinium-225 PSMA for men with advanced prostate cancer that has stopped responding to hormone therapy and has already been treated with Lu-177 PSMA (a similar targeted radiation therapy). It aims to see if this stronger radiation can help when the first type stops working.
LondonAges 18 years+ - NCT07432360Recruiting
Finding prostate cancer with advanced MRI and tissue analysis
This trial uses advanced MRI scans and detailed tissue analysis to better detect prostate cancer. It is for people with confirmed prostate cancer who are already scheduled for prostate removal surgery.
São PauloAges 18 years+ - NCT07441889RecruitingPhase 1/Phase 2
HER2-targeting immune cells for metastatic breast and prostate cancer
This trial tests a new treatment using specially designed immune cells that target HER2, a protein found on some cancer cells. It is for people with metastatic breast or prostate cancer that has worsened after prior treatments.
Charlottesville, VirginiaAges 18 years+ - NCT07531329Recruiting
Delayed PSMA imaging to detect aggressive prostate cancer
This study tests whether a special type of imaging scan (PSMA PET/CT with delayed imaging) can better identify aggressive prostate cancer in men who haven't had a biopsy yet. The goal is to help doctors decide who really needs a biopsy and avoid unnecessary procedures.
Lanzhou, GansuAges 18 years+ - NCT07541911Recruiting
Confocal Microscopy to Check Prostate Cancer Surgery Margins
This study tests whether a special microscope can help surgeons see cancer margins (edges) during prostate removal surgery to make sure all cancer is removed. It may help surgeons make real-time decisions about how much tissue to remove.
LondonAges 18 years+ - NCT07553780Recruiting
Tracking Prostate Cancer Response Using PSMA Imaging Scans
This study uses a special type of imaging scan (PSMA PET) to track how well prostate cancer treatment is working by comparing scans before and after your planned therapy. The goal is to help doctors better understand which treatments work best for your type of cancer.
Lanzhou, GansuAges 18 years+ - NCT07562438RecruitingPhase 2
Lutetium-177 Treatment for Advanced Prostate Cancer
This trial tests a radioactive medication (177Lu-P17-088) designed to target and treat prostate cancer that has spread to other parts of the body and stopped responding to hormone therapy. The medication is guided to cancer cells using a special imaging scan, potentially offering a new treatment option for men who have already tried other standard therapies.
Fuzhou, FujianAges 18–90 - NCT07614256Recruiting
Imaging and pathology analysis to predict prostate cancer
This study uses advanced imaging scans (MRI and ultrasound) and lab analysis of tissue samples to better predict prostate cancer. If you've had or are planning a prostate biopsy or surgery, your imaging and tissue results could help doctors develop better tools to diagnose prostate cancer.
Liuzhou, GuangxiAges 40–90 - NCT07635238RecruitingPhase 2
Lower Dose Radiation for Prostate Cancer
This trial tests whether a lower dose of radiation can effectively treat prostate cancer while reducing side effects. It is for men with certain types of prostate cancer that are visible on an MRI.
Basking Ridge, New JerseyAges 18 years+ - NCT07641049RecruitingPhase 1
CAR-NK Cell Therapy for Advanced Prostate Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target and fight advanced prostate cancer that has stopped responding to hormone treatments. The cells are engineered to recognize and attack cancer cells that have specific markers (PSMA and PSCA) on their surface.
Shenzhen, GuangdongAges 18 years+ - NCT07583160Enrolling by invitationPhase 1
YS247 Vaccine for Advanced Prostate Cancer
This trial tests a personalized cancer vaccine (YS247) designed to train your immune system to recognize and fight your prostate cancer. It may help slow or stop cancer growth in men whose cancer has spread and stopped responding to standard hormone treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT03423303Enrolling by invitation
Screening test to find early prostate cancer sooner
This trial checks whether an early prostate cancer screening approach can detect clinically significant prostate cancer sooner. It may help participants catch the disease at an earlier stage when treatment can be more effective.
HelsinkiAges 50–63 - NCT06236139RecruitingPhase 1/Phase 2
Immune cells plus hormone therapy for advanced prostate cancer
This study tests a new type of treatment that uses your own immune cells (engineered to target prostate cancer) combined with a hormone therapy drug. It is for men with advanced prostate cancer that has stopped responding to standard hormone treatments.
Seattle, WashingtonAges 18 years+ - NCT07135271Recruiting
Decision Support Tool for Newly Diagnosed Localised Prostate Cancer
This trial is testing a new decision support tool (BeSpoke) to help men with newly diagnosed localised prostate cancer make informed choices about their treatment. If you are deciding between two or more standard treatments, this tool may help you and your doctor pick the best one for you.
LondonAges Any age - NCT06490328RecruitingPhase 3
A new treatment for men with prostate cancer
This trial tests an investigational drug called DKF-MA102 for men with prostate cancer. The study aims to see if this drug can help control the cancer while keeping testosterone levels within a certain range.
SeoulAges 19 years+ - NCT07198633RecruitingPhase 1/Phase 2
Study of new drugs for advanced prostate cancer
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06335914Recruiting
Dual PET scans for advanced prostate cancer
This study tests whether two kinds of PET scans, one targeting PSMA and one targeting sugar uptake (FDG), can help doctors better understand advanced prostate cancer. If you have prostate cancer that has spread (metastatic) and still responds to hormone therapy, the scans may help guide your treatment.
Toronto, OntarioAges 18 years+ - NCT05011383RecruitingPhase 2
High dose testosterone for prostate cancer with ATM, CDK12, or CHEK2 changes
This trial is testing whether high doses of testosterone can help treat advanced prostate cancer in men who have a specific genetic change (ATM, CDK12, or CHEK2). It is for patients whose cancer has stopped responding to current hormone therapies.
Aurora, ColoradoAges 18 years+ - NCT03237026Recruiting
Urine tests to predict outcomes in prostate cancer treatment
This study looks for urine markers (proteins and metabolites) that may help predict how prostate cancer patients respond to treatment and what their outcomes are. You may be asked to give a urine sample and allow use of your medical and treatment details for analysis (results are not shared with you).
TaipeiAges 30–100 - NCT05191680RecruitingPhase 2
Testing apalutamide in early prostate cancer active surveillance
This Phase 2 trial tests whether apalutamide can help people with early prostate cancer who choose active surveillance. It uses MRI and biopsy results to confirm the cancer type and location, then checks if treatment is safe and potentially helpful.
Cambridge, CambridgeshireAges 18 years+
Hear when a new Clinically Significant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clinically significant prostate cancer?
- Yes. Clin2 currently lists 307 recruiting clinically significant prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clinically significant prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clinically significant prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.